More Money! Why Tekmira is Worth Revisiting
Research - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read nowAuthor Archives: Editorial Staff
PropThink’s Weekly Recap
Recap - We ended the week with some commentary based largely on the strength observed in recent biotech stocks immediately following financings. It’s the momentum behind recent secondary offerings – … Continue Reading
Read nowThe Sector Got Whacked on Friday
Recap - Sarepta Therapeutics (SRPT) on Thursday morning released its fourth quarter and full-year 2013 financial results. The company continues to await guidance from the FDA on the … Continue Reading
Read now
Our Unfortunate Timing, Though the Thesis Remains
Insights - Our timing couldn't have been much worse this week, though our thesis is intact on this nutraceutical business.
PremiumWhat We’re Trading, What We’re Stalking
Recap - Shares of Tekmira Pharmaceuticals (TKMR) have been on an absolute tear. Already since our January 7th reiteration to PropThink Premium members to own the stock, TKMR is up a … Continue Reading
Read nowPat Yourself on the Back
Recap - Just remember – it’s not a win until you’ve locked in those profits. Buying Retrophin (RTRX) when PropThink suggested going long the stock on the day it up-listed to … Continue Reading
Read now
Events Aligned for Alcobra in 2014 But There’s More to the Story
Research - Alcobra Ltd. (ADHD) is a clinical stage biopharmaceutical company that was founded in 2008 and hit the public stage in 2013. Alcobra currently trades at … Continue Reading
Premium